Note that this is for a very hard cancer to treat, and no one was expecting the great results seen here. Upcoming studies will focus on other cancer types where we expect results to be even better.
Disclaimer: I'm an investor in Ultimovacs and run a community for Ultimovacs investors at tekinvestor.no (in Norwegian, but google translate can help :))
"Ultimovacs is evaluating the universal cancer vaccine UV1 in a broad clinical development program across various cancer indications with different biologies and disease stages, in combination with different checkpoint inhibitors. The topline data from NIPU are the first results among the five randomized trials in the UV1 Phase II clinical program. In addition to malignant mesothelioma, Phase II studies are ongoing in patients with malignant melanoma, head and neck cancer, ovarian cancer, and non-small cell lung cancer. The topline data from the malignant melanoma and head and neck cancer trials are expected during the first and second half of 2024. UV1 is a patented, proprietary technology owned by Ultimovacs."
Our dog also likely had this in late august. Started with vomiting, then diarrhea every hour or so for a week. Scariest period we have had as dogowners. Dogs were likely getting sick for a while before the media picked it up.
Disclaimer: I'm an investor in Ultimovacs and run a community for Ultimovacs investors at tekinvestor.no (in Norwegian, but google translate can help :))
"Ultimovacs is evaluating the universal cancer vaccine UV1 in a broad clinical development program across various cancer indications with different biologies and disease stages, in combination with different checkpoint inhibitors. The topline data from NIPU are the first results among the five randomized trials in the UV1 Phase II clinical program. In addition to malignant mesothelioma, Phase II studies are ongoing in patients with malignant melanoma, head and neck cancer, ovarian cancer, and non-small cell lung cancer. The topline data from the malignant melanoma and head and neck cancer trials are expected during the first and second half of 2024. UV1 is a patented, proprietary technology owned by Ultimovacs."